Trevi Therapeutics
TRVI
20 hedge funds and large institutions have $45.9M invested in Trevi Therapeutics in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
25% more funds holding
Funds holding: 16 → 20 (+4)
1.2% less ownership
Funds ownership: 79.48% → 78.28% (-1.2%)
14% less capital invested
Capital invested by funds: $53.2M → $45.9M (-$7.23M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$318K |
| 2 |
BlackRock
New York
|
+$7.83K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$7.3K |
| 4 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$4.54K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$497K |
| 2 |
PCM
Pinz Capital Management
New York
|
-$377K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$228K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$48.6K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$34.7K |
TRVI Hedge Fund Activity: Q1 2020 in Review
20 of the 4,546 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q1 2020, worth a combined $45.9M — down 14% from $53.2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TRVI positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Banco Bilbao Vizcaya Argentaria, opening a new position worth an estimated $318K. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $497K.
- 20 institutional investors held Trevi Therapeutics (TRVI) as of Q1 2020, up from 16 in Q4 2019.
- Funds reported $45.9M of Trevi Therapeutics stock for Q1 2020, down 14% quarter-over-quarter.
- 6 funds opened new Trevi Therapeutics positions in Q1 2020 and 2 closed out, a net change of +4 holders.
- The largest Trevi Therapeutics buyer in Q1 2020 was Banco Bilbao Vizcaya Argentaria, an estimated $318K added.
- The largest Trevi Therapeutics seller in Q1 2020 was Schonfeld Strategic Advisors, an estimated $497K sold.
Based on aggregated 13F filings for Q1 2020.